Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Phase 1STAT6 DegraderPositive

AI Analysis

Summary

Nurix announced a $10 million milestone payment associated with the initiation of a Phase 1 clinical trial for its oral STAT6 degrader candidate in type 2 inflammatory diseases.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Phase 1 clinical trial initiated

Importance:6/10

Sentiment:

0.60

Phase 1 TrialSTAT6 DegraderMilestone PaymentInflammatory DiseasesOral Therapeutic

Related Companies

$NRIX

Read the original article

Published by GlobeNewswire Pharma on August 4, 2026 11:00 AM

Read Original